Beam's risto-cel hits endpoint in sickle cell BEACON trial
Beam Therapeutics' base editing therapy risto-cel achieved its primary endpoint of 12 months without severe pain crises in a key trial, setting up a planned FDA submission.
Beam Therapeutics' risto-cel therapy met the primary endpoint in its key BEACON trial for sickle cell disease. The one-time treatment provided at least 12 consecutive months of freedom from severe vaso-occlusive crises for 31 patients with 12 months of follow-up.
Risto-cel also succeeded on all secondary endpoints, including freedom from hospitalization for severe crises for at least 12 consecutive months. The trial met all primary safety endpoints in an interim analysis, with a safety profile consistent with the effects of stem cell transplantation.
Trial design and patient population
The Phase 1/2 BEACON trial investigated ristoglogene autogetemcel, or risto-cel, in patients with sickle cell disease and a history of severe vaso-occlusive crises. As of an October data cutoff, 39 adults and 10 adolescents had been treated with the one-time therapy.
Risto-cel is an ex vivo autologous cell therapy. It is made by extracting a patient's own CD34+ hematopoietic stem and progenitor cells, then base-editing them in the promoter regions of the HBG1 and HBG2 genes. These genes encode fetal hemoglobin. The editing inhibits BCL11A, which increases fetal hemoglobin production to treat the disease. The re-engineered cells are then transplanted back into the patient.
Regulatory pathway and competitive landscape
Beam plans to submit a biologics license application for risto-cel to the US Food and Drug Administration as early as the end of 2026. This would position it as the third gene therapy for sickle cell disease, following Casgevy from Vertex Pharmaceuticals and CRISPR Therapeutics, and Lyfgenia from Genetix Biotherapeutics.
Beam's management has stated that limited uptake of the existing gene therapies is due to supply constraints, not issues with demand or reimbursement. The company's CEO, John Evans, said the results represent a defining milestone for risto-cel and for Beam’s base editing technology more broadly.
Safety and manufacturing advantages
The therapy demonstrated a favorable safety profile consistent with stem cell transplantation effects. Beam also highlights potential manufacturing advantages for risto-cel compared to existing therapies.
It has a shorter manufacturing process and requires fewer treatment cycles. Detailed key results from the BEACON study are planned for presentation at a medical meeting in 2027. Beam expects to submit its application to the FDA as early as the end of 2026.
